-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that long-term data from two phase 3 clinical trials of Johnson & Johnson (JNJ.US) showed that adult patients with Crohn's disease treated with Tremfya (guseciumab) had a clinical remission rate of up to 94% within three years.

Zhitongcaijing·10/13/2026 01:49:07
Listen to the news
The Zhitong Finance App learned that long-term data from two phase 3 clinical trials of Johnson & Johnson (JNJ.US) showed that adult patients with Crohn's disease treated with Tremfya (guseciumab) had a clinical remission rate of up to 94% within three years.